This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.

Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.


2qi3

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 1: Line 1:
-
[[Image:2qi3.jpg|left|200px]]
+
{{Seed}}
 +
[[Image:2qi3.png|left|200px]]
<!--
<!--
Line 9: Line 10:
{{STRUCTURE_2qi3| PDB=2qi3 | SCENE= }}
{{STRUCTURE_2qi3| PDB=2qi3 | SCENE= }}
-
'''Crystal structure of protease inhibitor, MIT-2-AD94 in complex with wild type HIV-1 protease'''
+
===Crystal structure of protease inhibitor, MIT-2-AD94 in complex with wild type HIV-1 protease===
-
==Overview==
+
<!--
-
The acquisition of drug-resistant mutations by infectious pathogens remains a pressing health concern, and the development of strategies to combat this threat is a priority. Here we have applied a general strategy, inverse design using the substrate envelope, to develop inhibitors of HIV-1 protease. Structure-based computation was used to design inhibitors predicted to stay within a consensus substrate volume in the binding site. Two rounds of design, synthesis, experimental testing, and structural analysis were carried out, resulting in a total of 51 compounds. Improvements in design methodology led to a roughly 1000-fold affinity enhancement to a wild-type protease for the best binders, from a Ki of 30-50 nM in round one to below 100 pM in round two. Crystal structures of a subset of complexes revealed a binding mode similar to each design that respected the substrate envelope in nearly all cases. All four best binders from round one exhibited broad specificity against a clinically relevant panel of drug-resistant HIV-1 protease variants, losing no more than 6-13-fold affinity relative to wild type. Testing a subset of second-round compounds against the panel of resistant variants revealed three classes of inhibitors: robust binders (maximum affinity loss of 14-16-fold), moderate binders (35-80-fold), and susceptible binders (greater than 100-fold). Although for especially high-affinity inhibitors additional factors may also be important, overall, these results suggest that designing inhibitors using the substrate envelope may be a useful strategy in the development of therapeutics with low susceptibility to resistance.
+
The line below this paragraph, {{ABSTRACT_PUBMED_18412349}}, adds the Publication Abstract to the page
 +
(as it appears on PubMed at http://www.pubmed.gov), where 18412349 is the PubMed ID number.
 +
-->
 +
{{ABSTRACT_PUBMED_18412349}}
==About this Structure==
==About this Structure==
Line 28: Line 32:
[[Category: Hydrolase]]
[[Category: Hydrolase]]
[[Category: Protease inhibitor]]
[[Category: Protease inhibitor]]
-
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu May 22 22:28:24 2008''
+
 
 +
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Tue Jul 29 06:22:52 2008''

Revision as of 03:22, 29 July 2008

Image:2qi3.png

Template:STRUCTURE 2qi3

Crystal structure of protease inhibitor, MIT-2-AD94 in complex with wild type HIV-1 protease

Template:ABSTRACT PUBMED 18412349

About this Structure

2QI3 is a Single protein structure of sequence from Human immunodeficiency virus 1. Full crystallographic information is available from OCA.

Reference

HIV-1 protease inhibitors from inverse design in the substrate envelope exhibit subnanomolar binding to drug-resistant variants., Altman MD, Ali A, Reddy GS, Nalam MN, Anjum SG, Cao H, Chellappan S, Kairys V, Fernandes MX, Gilson MK, Schiffer CA, Rana TM, Tidor B, J Am Chem Soc. 2008 May 14;130(19):6099-113. Epub 2008 Apr 16. PMID:18412349

Page seeded by OCA on Tue Jul 29 06:22:52 2008

Proteopedia Page Contributors and Editors (what is this?)

OCA

Retrieved from "http://52.214.119.220/wiki/index.php/2qi3"
Personal tools